Vyome Holdings, Inc
No enriched coverage for $HIND in the last 7 days.
No SEC Form 4 filings for $HIND in the last 30 days.
See all $HIND insider activity →Vyome Therapeutics (HIND) presented its strategy at Chardan's healthcare conference, focusing on VT-1953, a topical gel for malignant fungating wounds. The company reported Q2 operating expenses of $874,000 and shared encouraging early data from a Phase II study. Vyome aims to conserve capital and targets rare diseases with unmet needs, engaging with the FDA for further discussions.
The Fed updated projections, now seeing the federal funds rate at 4.1% by 2026, up from 3.8% in June, indicating another hike. CFOs face higher costs for floating-rate credit and new issuances. Yiming Ma, a finance professor, advises stress testing funding and production costs together. Markets reacted negatively, with Treasury yields rising. Vyome and Zelis appointed new CFOs. A report found 83% of executives made decisions based on outdated forecasts, with 40% facing significant consequences.
Vyome Holdings, Inc (HIND) filed an SEC Form 8-K — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers. Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. On August 27, 2026, the board of directors (the “Board”) of Vyome Holdings, Inc. (the “Company”) appointed Jerry Leonard as
Recent HIND coverage spans financial news, macro economy and corporate actions.
Vyome Therapeutics (HIND) presented its strategy at Chardan's healthcare conference, focusing on VT-1953, a topical gel for malignant fungating wounds. The company reported Q2 operating expenses of $874,000 and shared encouraging early data from a Phase II study. Vyome aims to conserve capital and targets rare diseases with unmet needs, engaging with the FDA for further discussions.
Neutral impact; CFO change may affect future financial strategy but no immediate market move.
The CFO change is a routine corporate action with limited immediate price impact.
Positive Phase 2 outcomes and FDA feedback may boost near‑term valuation; cash runway remains limited.
AlphAI scores every news story that mentions HIND with an AI model for sentiment and relevance, and aggregates insider trades from Vyome Holdings, Inc's SEC EDGAR Form 4 filings. Figures refresh continuously.
Vyome Therapeutics (HIND) presented its strategy at Chardan's healthcare conference, focusing on VT-1953, a topical gel for malignant fungating wounds. The company reported Q2 operating expenses of $874,000 and shared encouraging early data from a Phase II study. Vyome aims to conserve capital and targets rare diseases with unmet needs, engaging with the FDA for further discussions.
3 min readThe Fed updated projections, now seeing the federal funds rate at 4.1% by 2026, up from 3.8% in June, indicating another hike. CFOs face higher costs for floating-rate credit and new issuances. Yiming Ma, a finance professor, advises stress testing funding and production costs together. Markets reacted negatively, with Treasury yields rising. Vyome and Zelis appointed new CFOs. A report found 83% of executives made decisions based on outdated forecasts, with 40% facing significant consequences.
2 min readVyome Holdings, Inc (HIND) filed an SEC Form 8-K — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers. Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. On August 27, 2026, the board of directors (the “Board”) of Vyome Holdings, Inc. (the “Company”) appointed Jerry Leonard as
1 min readVyome Holdings, Inc (HIND) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Vyome Holdings Reports Second Quarter 2026 Results Highlighted By Advancement Of Lead VT-1953 Program, Pipeline Expansion And Strong Balance Sheet CAMBRIDGE, Mass., August 25, 2026 — Vyome Holdings, Inc. (“Vyome”), a clinical-stage biopharmaceutical company focused o
2 min read
